6BIO

Inibitor of phosphoinositide-dependent kinase 1 and GSK



ALX-430-156-M001	1 mg	53.00 USD

ALX-430-156-M005	5 mg	104.00 USD

ALX-430-156-M025	25 mg	416.00 USD

Inhibitor of phosphoinositide-dependent kinase 1 (PDK1). Potent, reversible and ATP-competitive inhibitor of glycogen synthase kinase-3α/β (GSK-3α/β) (IC₅₀=5nM).

Product Specification

Alternative Name:	(2’Z,3’E)-6-Bromoindirubin-3’-oxime

Formula:	C₁₆H₁₀BrN₃O₂

MW:	356.2

Purity:	≥98%

Appearance:	Dark red solid.

CAS:	667463-62-9

Solubility:	Soluble in DMSO.

Long Term Storage:	-20°C

Hazard:	IRRITANT.

Handling:	Protect from light.

Please mouse over

Product Literature References

Glycogen synthase kinase-3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production: A. Valerio, et al.; J. Neurochem. 116, 1148 (2011), Abstract;

Anticancer effects and antimetastatic mechanisms of novel indirubin derivatives: C.A. Kressirer; PhD Thesis (2010), Full Text

Wnt/beta-catenin and retinoic acid receptor signaling pathways interact to regulate chondrocyte function and matrix turnover: R. Yasuhara, et al.; J. Biol. Chem. 285, 317 (2010), Abstract; Full Text

Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A: L. Martin, et al.; Brain Res. 1252, 66 (2009), Abstract;

An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins: V. Myrianthopoulos, et al.; J. Med. Chem. 50, 4027 (2007), Abstract;

Inverse in silico screening for identification of kinase inhibitor targets: S. Zahler, et al.; Chem. Biol. 14, 1207 (2007), Abstract;

7-Bromoindirubin-3’-oxime induces caspase-independent cell death: J. Ribas, et al.; Oncogene 25, 6304 (2006), Abstract;

The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes: A.S. Tseng, et al.; Chem. Biol. 13, 957 (2006), Abstract;

Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases: P. Polychronopoulos, et al.; J. Med. Chem. 47, 935 (2004), Abstract;

GSK-3-selective inhibitors derived from Tyrian purple indirubins: L. Meijer, et al.; Chem. Biol. 10, 1255 (2003), Abstract;